Market Cap 5.55B
Revenue (ttm) 434.43M
Net Income (ttm) 275.19M
EPS (ttm) N/A
PE Ratio 140.98
Forward PE N/A
Profit Margin 63.35%
Debt to Equity Ratio 0.00
Volume 154,000
Avg Vol 984,516
Day's Range N/A - N/A
Shares Out 62.52M
Stochastic %K 38%
Beta 2.19
Analysts Strong Sell
Price Target $94.50

Company Profile

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 474 0170
Address:
7707 Gateway Boulevard, Suite 140, Newark, United States
biochirp
biochirp Dec. 22 at 4:25 PM
$ABVX J&J losing here means they’re forced to pickup $PTGX
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 19 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:01 PM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $85.79, showing a neutral sentiment with an RSI of 42.74, indicating potential for upward movement as it is below the 50 threshold. The stock is also below the 30-day moving average (MA30) of $87.16, suggesting bearish pressure, but above the 50-day moving average (MA50) of $82.95, indicating support. Directional Bias: With the current price near the lower end of the 60-day range ($62.24 - $96.54), there is room for recovery. The ATR of 3.53 suggests moderate volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $85.79 - Stop Loss: $82.50 (approximately 3% below entry) - Take Profit Targets: - Target 1: $90.00 (5% ROI) - Target 2: $95.00 (10.5% ROI) - Target 3: $100.00 (17% ROI) This trade plan capitalizes on potential upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 17 at 8:11 PM
$PTGX re-entered. Look forward to rusfertide approval, further development of icotrokinra, and advancement of PN-881 (oral IL-17 antagonist).
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 5:54 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 88 → 108.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:46 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $91.54, showing a stable price action with an RSI of 53.57, indicating neutral momentum. The stock is positioned above both the 30-day MA (86.47) and the 50-day MA (82.06), suggesting a bullish trend in the short to medium term. Directional Bias: The price is approaching the 60-day high of $96.54, indicating potential upward momentum. The RSI is neither overbought nor oversold, allowing room for further gains. Trade Plan: - Suggested Entry: $92.00 - Stop Loss: $88.00 (4.35% below entry) - Take Profit Targets: 1. Target 1: $95.00 (3.26% gain) 2. Target 2: $97.50 (5.43% gain) 3. Target 3: $107.00 (16.48% gain) With this setup, achieving a 17% ROI or more on the final target is feasible. Monitor the price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:19 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX closed at $95.35, just above its 60D high of $95.39, indicating potential resistance. The RSI at 70.58 suggests overbought conditions, which may lead to a pullback. However, the strong performance relative to the MA30 (85.41) and MA50 (80.91) indicates bullish momentum. Directional Bias: Despite the overbought RSI, the stock's position above key moving averages signals strength. The recent high-low range (60D High: $95.39, 60D Low: $61.63) shows significant volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $95.50 - Stop Loss: $92.00 (3.3% below entry) - Take Profit Targets: 1. $100.00 (4.9% ROI) 2. $105.00 (9.5% ROI) 3. $112.00 (17.4% ROI) With this plan, you can capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 13 at 9:22 PM
0 · Reply
blueb22
blueb22 Dec. 12 at 7:57 PM
$PTGX - J&J BO should come out next week, otherwise it would be during JPM conference week. They have to buy it now. Other short term catalyst would be BLA filling for PV drug (reta) - PR could come today or by next Friday.
0 · Reply
Latest News on PTGX
RTW Investments' Rod Wong: Expect more deals in biotech space

Oct 10, 2025, 1:21 PM EDT - 2 months ago

RTW Investments' Rod Wong: Expect more deals in biotech space

JNJ XBI


Johnson & Johnson in Talks to Buy Protagonist Therapeutics

Oct 10, 2025, 11:13 AM EDT - 2 months ago

Johnson & Johnson in Talks to Buy Protagonist Therapeutics

JNJ


Protagonist Therapeutics Reports Granting of Inducement Award

Apr 16, 2025, 4:05 PM EDT - 9 months ago

Protagonist Therapeutics Reports Granting of Inducement Award


Overlooked Stock: PTGX

Mar 10, 2025, 4:57 PM EDT - 10 months ago

Overlooked Stock: PTGX


Why Is Protagonist Therapeutics Stock Trading Higher On Monday?

Mar 10, 2025, 10:04 AM EDT - 10 months ago

Why Is Protagonist Therapeutics Stock Trading Higher On Monday?


biochirp
biochirp Dec. 22 at 4:25 PM
$ABVX J&J losing here means they’re forced to pickup $PTGX
0 · Reply
Quantumup
Quantumup Dec. 22 at 11:32 AM
a/o Friday: BMO Capital reiterated $IRON Outperform/$120 Jefferies reiterated Buy/$154 TD Cowen reiterated Buy Stifel analyst reiterated Buy/$125 $CLVLY Mitsubishi Tanabe Pharma $NVS ABBV GERN $PTGX - $TAK Here's what the Analysts had to say on Friday:
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 19 at 10:21 PM
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:01 PM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $85.79, showing a neutral sentiment with an RSI of 42.74, indicating potential for upward movement as it is below the 50 threshold. The stock is also below the 30-day moving average (MA30) of $87.16, suggesting bearish pressure, but above the 50-day moving average (MA50) of $82.95, indicating support. Directional Bias: With the current price near the lower end of the 60-day range ($62.24 - $96.54), there is room for recovery. The ATR of 3.53 suggests moderate volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $85.79 - Stop Loss: $82.50 (approximately 3% below entry) - Take Profit Targets: - Target 1: $90.00 (5% ROI) - Target 2: $95.00 (10.5% ROI) - Target 3: $100.00 (17% ROI) This trade plan capitalizes on potential upward momentum while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 17 at 8:11 PM
$PTGX re-entered. Look forward to rusfertide approval, further development of icotrokinra, and advancement of PN-881 (oral IL-17 antagonist).
0 · Reply
JarvisFlow
JarvisFlow Dec. 17 at 5:54 PM
Barclays updates rating for Protagonist Therapeutics ( $PTGX ) to Overweight, target set at 88 → 108.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 3:46 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $91.54, showing a stable price action with an RSI of 53.57, indicating neutral momentum. The stock is positioned above both the 30-day MA (86.47) and the 50-day MA (82.06), suggesting a bullish trend in the short to medium term. Directional Bias: The price is approaching the 60-day high of $96.54, indicating potential upward momentum. The RSI is neither overbought nor oversold, allowing room for further gains. Trade Plan: - Suggested Entry: $92.00 - Stop Loss: $88.00 (4.35% below entry) - Take Profit Targets: 1. Target 1: $95.00 (3.26% gain) 2. Target 2: $97.50 (5.43% gain) 3. Target 3: $107.00 (16.48% gain) With this setup, achieving a 17% ROI or more on the final target is feasible. Monitor the price action closely for adjustments. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:19 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX closed at $95.35, just above its 60D high of $95.39, indicating potential resistance. The RSI at 70.58 suggests overbought conditions, which may lead to a pullback. However, the strong performance relative to the MA30 (85.41) and MA50 (80.91) indicates bullish momentum. Directional Bias: Despite the overbought RSI, the stock's position above key moving averages signals strength. The recent high-low range (60D High: $95.39, 60D Low: $61.63) shows significant volatility, providing opportunities for profit. Trade Plan: - Suggested Entry: $95.50 - Stop Loss: $92.00 (3.3% below entry) - Take Profit Targets: 1. $100.00 (4.9% ROI) 2. $105.00 (9.5% ROI) 3. $112.00 (17.4% ROI) With this plan, you can capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
Sw1ngb0t
Sw1ngb0t Dec. 13 at 9:22 PM
0 · Reply
blueb22
blueb22 Dec. 12 at 7:57 PM
$PTGX - J&J BO should come out next week, otherwise it would be during JPM conference week. They have to buy it now. Other short term catalyst would be BLA filling for PV drug (reta) - PR could come today or by next Friday.
0 · Reply
biochirp
biochirp Dec. 12 at 6:32 PM
$PTGX J&J wants this badly
0 · Reply
biochirp
biochirp Dec. 12 at 6:31 PM
$CYTK JPM names should start going here $VKTX $ABVX $PTGX
0 · Reply
Quantumup
Quantumup Dec. 12 at 12:49 PM
Citizens reiterated $PTGX Market Outperform/$102. $TAK $JNJ Citizens said in its note: PTGX has a big decision coming up by mid-2026 when management has to determine whether to opt out of its 50/50 U.S. profit/loss share for rusfertide with Takeda, which would change PTGX's downstream economics. We assume PTGX will opt out to bring in more risk-free cash that the company can deploy to advance its earlier-stage internal pipeline.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 12 at 12:13 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $92.64, near its 60-day high of $93.25, indicating bullish momentum. The RSI at 68.62 suggests it is approaching overbought territory, which may lead to a pullback. However, the strong position above the 30-day MA (84.84) and 50-day MA (80.31) supports a bullish bias. Directional Bias: The upward trend is reinforced by the price being significantly above both MAs, indicating strong buying interest. Trade Plan: - Suggested Entry: $92.50 - Stop Loss: $89.80 (below recent support) - Take Profit Targets: 1. Target 1: $95.00 (3% gain) 2. Target 2: $97.50 (5% gain) 3. Target 3: $108.00 (16.5% gain) With a potential ROI of over 17% on Target 3, this trade offers a favorable risk-reward ratio. Monitor RSI for overbought signals and adjust targets as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 4:16 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $88.56, showing bullish momentum with an RSI of 60.3, indicating upward strength but approaching overbought territory. The stock is above both the 30-day MA (83.88) and 50-day MA (79.24), reinforcing a positive trend. Directional Bias: The recent price action is strong, with the stock trading closer to the 60D high of $93.25. Given the current RSI and MAs, we maintain a bullish outlook. Trade Plan: - Suggested Entry: $88.56 - Stop Loss: $85.75 (below the 30-day MA, providing a cushion against volatility) - Take Profit Targets: 1. $91.00 (3% gain) 2. $93.00 (5% gain) 3. $103.00 (16.3% gain) This plan allows for a minimum 17% ROI on the third target while managing risk effectively. Monitor price action closely, and adjust targets as necessary. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 9 at 12:05 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX closed at $90.42, showing a bullish trend with strong momentum. The RSI at 64.78 indicates that the stock is nearing overbought territory but still has room for further gains. The MA30 at $83.44 and MA50 at $78.77 suggest a solid upward trend, reinforcing a bullish bias. Directional Bias: The stock is currently above both the MA30 and MA50, indicating strong support levels. The recent high of $93.25 suggests potential resistance, but with the current momentum, a breakout is possible. Trade Plan: - Suggested Entry: $90.50 - Stop Loss: $87.00 (3.5% below entry) - Take Profit Targets: 1. Target 1: $93.00 (2.8% gain) 2. Target 2: $95.00 (4.1% gain) 3. Target 3: $106.00 (17.2% gain) This strategy aims for a minimum ROI of 17% on the third target while maintaining a manageable risk. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 8 at 7:43 PM
Citigroup has adjusted their stance on Protagonist Therapeutics ( $PTGX ), setting the rating to Buy with a target price of 98 → 115.
0 · Reply
prismmarketview
prismmarketview Dec. 8 at 4:33 PM
Protagonist Therapeutics’(NASDAQ: $PTGX) and Takeda (NYSE: $TAK), Rusfertide continues to impress in PV, with Phase 3 VERIFY data showing durable 52-week hematocrit control, a double-digit fold reduction in annual phlebotomy rates, and sustained responses that strengthen its first-in-class profile. https://prismmarketview.com/protagonist-therapeuticss-rusfertide-delivers-durable-results-in-phase-iii/
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 7 at 11:34 PM
$PTGX $TAK Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera "52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints"
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:04 AM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $87.33, showing bullish momentum with an RSI of 61.65, indicating potential for further upside. The stock is above its 30-day moving average (MA30) of 82.4 and 50-day moving average (MA50) of 77.82, suggesting strong upward momentum. Directional Bias: The stock is in a bullish trend, as confirmed by its position relative to key moving averages and the recent high of $93.25, which is only 6.7% above the current price. Trade Plan: - Suggested Entry: $87.50 - Stop Loss: $84.50 (risking $3.00, approx. 3.4%) - Take Profit Targets: 1. TP1: $90.00 (3% gain) 2. TP2: $92.00 (5.7% gain) 3. TP3: $102.00 (16.7% gain) With a potential 16.7% ROI on TP3, this trade aligns well with the current market conditions. Monitor closely for any volatility, as indicated by an ATR of 2.77. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 6 at 1:51 AM
$PTGX Current Stock Price: $89.62 Contracts to trade: $90 PTGX Dec 19 2025 Call Entry: $2.00 Exit: $3.68 ROI: 84% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:39 PM
Actionable Trade Alert for $PTGX: Market Context: $PTGX is currently trading at $87.33, showing bullish momentum with an RSI of 61.65, indicating potential for further upside. The stock is above its 30-day moving average (MA30) of 82.4 and 50-day moving average (MA50) of 77.82, suggesting strong upward momentum. Directional Bias: The stock is in a bullish trend, as confirmed by its position relative to key moving averages and the recent high of $93.25, which is only 6.7% above the current price. Trade Plan: - Suggested Entry: $87.50 - Stop Loss: $84.50 (risking $3.00, approx. 3.4%) - Take Profit Targets: 1. TP1: $90.00 (3% gain) 2. TP2: $92.00 (5.7% gain) 3. TP3: $102.00 (16.7% gain) With a potential 16.7% ROI on TP3, this trade aligns well with the current market conditions. Monitor closely for any volatility, as indicated by an ATR of 2.77. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply